These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36398619)

  • 1. Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.
    Peterson JS; Plana D; Bitterman DS; Johnson SB; Aerts HJWL; Kann BH
    Cancer Med; 2023 Feb; 12(4):4715-4724. PubMed ID: 36398619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.
    Massett HA; Mishkin G; Rubinstein L; Ivy SP; Denicoff A; Godwin E; DiPiazza K; Bolognese J; Zwiebel JA; Abrams JS
    Clin Cancer Res; 2016 Nov; 22(22):5408-5416. PubMed ID: 27401246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
    Tang C; Sherman SI; Price M; Weng J; Davis SE; Hong DS; Yao JC; Buzdar A; Wilding G; Lee JJ
    Clin Cancer Res; 2017 Mar; 23(6):1414-1421. PubMed ID: 28275168
    [No Abstract]   [Full Text] [Related]  

  • 4. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2011 Apr; 17(7):1947-55. PubMed ID: 21447723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
    Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
    Korn EL; Freidlin B; Mooney M; Abrams JS
    J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.
    Carpenter WR; Fortune-Greeley AK; Zullig LL; Lee SY; Weiner BJ
    Contemp Clin Trials; 2012 Jan; 33(1):46-54. PubMed ID: 21986391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights From Building a New National Cancer Institute Community Oncology Research Program Site.
    Saphner T; Thompson MA; Planton S; Singh M; Glandt N; Robinson L; DeBartolo J
    WMJ; 2016 Aug; 115(4):191-5. PubMed ID: 29099156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Clinical Trial Accrual Predictive Regression Model at a Single NCI-Designated Comprehensive Cancer Center.
    Tate WR; Cranmer LD
    J Natl Compr Canc Netw; 2016 May; 14(5):561-9. PubMed ID: 27160234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accrual of older adults to cancer clinical trials led by the Canadian cancer trials group - Is trial design a barrier?
    Hernandez-Torres C; Cheung WY; Kong S; O'Callaghan CJ; Hsu T
    J Geriatr Oncol; 2020 Apr; 11(3):455-462. PubMed ID: 31473189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network.
    Sankaran H; Finnigan SR; McShane LM; Best AF; Seibel NL
    Cancer; 2022 Nov; 128(21):3843-3849. PubMed ID: 36089859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.
    Denicoff AM; McCaskill-Stevens W; Grubbs SS; Bruinooge SS; Comis RL; Devine P; Dilts DM; Duff ME; Ford JG; Joffe S; Schapira L; Weinfurt KP; Michaels M; Raghavan D; Richmond ES; Zon R; Albrecht TL; Bookman MA; Dowlati A; Enos RA; Fouad MN; Good M; Hicks WJ; Loehrer PJ; Lyss AP; Wolff SN; Wujcik DM; Meropol NJ
    J Oncol Pract; 2013 Nov; 9(6):267-76. PubMed ID: 24130252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
    Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
    Le-Rademacher J; Mohile S; Unger J; Hudson MF; Foster J; Lichtman S; Perlmutter J; Dotan E; Extermann M; Dodd K; Tew W; Klepin H; Wildes TM; Sedrak MS; Jatoi A; Little RF
    J Natl Cancer Inst Monogr; 2022 Dec; 2022(60):135-141. PubMed ID: 36519818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Through the Lens of Patient Partners: Challenges in Accrual of Older Adults to NCI Clinical Trials.
    BrintzenhofeSzoc K; Canin B; Casas-Silva E; Denicoff A; Braun-Inglis C; Okado I; Bakos A
    J Natl Cancer Inst Monogr; 2022 Dec; 2022(60):125-134. PubMed ID: 36519817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
    Baquet CR; Ellison GL; Mishra SI
    J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials.
    Baquet CR; Ellison GL; Mishra SI
    J Health Care Poor Underserved; 2009 May; 20(2 Suppl):120-34. PubMed ID: 19711497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.
    Kunos CA; Massett HA; Galassi A; Walker JL; Good MJ; Díaz LB; McCaskill-Stevens W
    Front Oncol; 2018; 8():102. PubMed ID: 29692980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.